University of Toyama | Date: 2012-06-06
A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.
Kracie Pharma Ltd., National Cancer Center and University of Toyama | Date: 2014-09-24
The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.
Sumitomo Chemical and University of Toyama | Date: 2013-08-01
A method of producing olefin having 2 to 4 carbon atoms, including a process of reacting at least one kind of a catalyst (D) selected from the group consisting of below catalysts (A) to (C) with synthesis gas in the presence of a dispersion medium through a Fischer-Tropsch reaction, in which the catalyst (A) contains iron and one to three kinds of elements selected from the group consisting of alkali metal and alkali earth metal, the catalyst (B) contains cobalt, provided that the catalyst (B) is a catalyst except a catalyst obtained by reducing a cobalt ion and an iron ion in a dispersion liquid or a solution containing the cobalt ion, the iron ion and a dispersant that interacts with the cobalt ion and the iron ion, and the catalyst (C) contains nickel or ruthenium.
University of Toyama | Date: 2013-03-06
An object of the present invention is to stimulate a T cell without using a peptide/MHC tetramer. In the present invention, the step of supplying an antigen peptide to a T cell having a T cell receptor (TCR) that can recognize the antigen peptide on cell surface to form a complex of a major histocompatibility complex (MHC) molecule on the cell surface of the T cell and the antigen peptide is used, and the T cell is stimulated through recognition by TCR of the antigen peptide as the MHC molecule-antigen peptide complex on the cell surface of the same T cell. Such a stimulating and activating method would be applicable to not only T cells, but also various cells. According to the present invention, an antigen-specific T cell can be identified without establishing any antigen-specific T cell strain, and without using such a reagent as MHC/peptide tetramer. That is, a cancer-specific T cell can be efficiently and conveniently identified.
University of Toyama | Date: 2013-07-24
An object is to provide a TCR closing system that enables not only bias-free analysis of TCR repertoires, but also collection of antigen-specific TCR / cDNA pairs and evaluation of functions thereof. There is provided a method for producing a gene of T cell receptor (TCR) specific to an antigen A, which comprises 1) the step of stimulating a group of T cells including a T cell specific to an antigen A or one T cell specific to an antigen A under a condition effective for amplification of a TCR gene; 2) the step of identifying a T cell specific to an antigen A among the group of T cells including a T cell specific to the antigen A, and sorting one T cell specific to the antigen A into a vessel; and 3) the step of subjecting the one activated T cell specific to the antigen A in the vessel to PCR to amplify a gene of TCR specific to the antigen A. According to the present invention, a target TCR gene can be cloned within a shorter time compared with that repaired by the conventional methods, for example, about ten days. Further, according to the present invention, genes of TCR chain and chain can be highly efficiently cloned. Under the conditions of the examples, a pair of a TCR chain and TCR chain could be obtained from stimulated T cells sorted as single cells at a ratio of 100%.